Work

Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.tps299

Authors: Qiyu Zhu, Jinge Zhao, Pengfei Shen, Ming Zhang, Qian Wang

Institutions: West China Hospital of Sichuan University, Sichuan University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407700329

FWCI:

Cites:

Cited by:

Related to: 10